Skip to the beginning of the images gallery

Building an Integrated Biopharma Company: Crucell (B)

Hamermesh, Richard G. ; Van Der Steen, Marianne ; Harmeling, Susan S.

Reference: HBS-815086-E
Number of pages: 2
Geographic Setting: Netherlands
Publication Date: Feb 25, 2015
Fecha de edición: Nov 6, 2015
Source: HBSP (USA)
Type of Document: Case
Industry Setting: Biotechnology;Pharmaceuticals

Grouped product items
Format	Language	Reference	Use	Qty	Price
pdf	English	HBS-815086-E			As low as €5.74

You already have a subscription

To order please contact the person in charge of academic purchases in your university.

You'll be able to order once your profile has been validated.

Description

The Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8 billion.

Keywords

Acquisition Entrepreneurship Global health Growth strategy Health care Innovation Licensing Negotiation Partnerships Strategy